GET DAILY SIGNALSSurgery Partners (SGRY): Can Shares Reach $28 in This Merger Scenario?
Key Takeaways
- The $28 central target comes from public merger discussion — an unsolicited, non-binding third-party cash offer reported by Reuters — rather than from an analyst consensus.
- Analyst price targets, which averaged roughly $19 to $23 and ranged from about $14 to $24, were largely published before the merger talks intensified and now sit near or below the share price; they are provided as context only, not as the target.
- The latest verified closing price was $23.20, implying roughly a 21% move to reach $28, which is a substantial but not extreme gap.
- The agreed deal with HealthSpan Partners offers $25 per share in cash (up to $26.61 with a ticking fee), anchoring downside while the $28 rival bid represents the upside scenario.
- The biggest risk is that the board deemed the $28 proposal not superior, citing regulatory and closing risk, and that any transaction still requires shareholder and regulatory approval.
- For more detail on Major News, Today's Price Move, a Forecast, and upcoming Earnings, explore the dedicated SGRY pages.
- For broader market scanning and automation, consider exploring Trending AI Robots.
How the $28 Target Came Into View
Surgery Partners, Inc. (SGRY), the Tennessee-based operator of ambulatory surgery centers and short-stay surgical hospitals, has shifted from a fundamental turnaround narrative into an event-driven merger situation. The question of whether the shares can reach $28 now centers more on the terms and completion risk of a pending take-private transaction than on earnings momentum alone. SGRY failed the standard analyst-price-target test because the average compiled before the merger news — between about $19 and $23, with a low-to-high range of roughly $14 to $24 — no longer exceeds the market price by a meaningful margin. Those targets predate the current deal dynamics. Instead, the $28 figure is drawn directly from public reporting: an unsolicited, non-binding cash proposal of $28 per share for all outstanding shares, received November 3 and updated November 8, 2026, according to Reuters. It is the highest price objective actually being discussed in the market for SGRY, and it clears the required threshold of being at least 10% above the latest close. I also checked this using Tickeron’s AI Daily Buy/Sell Signals to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
At its most recent close, SGRY traded at $23.20, near the top of a 52-week range spanning roughly $11.41 to $23.44. Reaching $28 would require a gain of about 21% from that close, a substantial move. In practice, the path is narrower than that percentage suggests: the stock surged roughly 12% in pre-market trading to around $25.78–$26 following the sweetened HealthSpan bid, meaning much of the gap toward $25 has already been priced in. The remaining distance to $28 depends almost entirely on deal developments — a raised competing bid, an improved definitive agreement, or a higher closing consideration — rather than on operating results alone. From what I see, reviewing the setup with Tickeron AI tools helped clarify the event-driven nature of the move.
What Could Support a Move Toward the Target
The clearest support is the merger itself. HealthSpan Partners, an affiliate of nonprofit hospital system Bon Secours Mercy Health, agreed to raise its cash consideration to $25 per share from $23.50, with a 10% annual ticking fee that can lift the total to a maximum of $26.61 per share if closing extends toward October 23, 2027. The transaction values SGRY at up to about $6 billion in enterprise value. Separately, a third party made a non-binding offer at $28 per share, and the possibility of a revised, superior proposal — or a bidding contest — is what keeps a move toward $28 on the table. Strategically, Bon Secours is betting on the long-running migration of surgical procedures into lower-cost outpatient settings, the same thesis that underpinned Ascension's earlier acquisition of AmSurg.
What Could Prevent the Target From Being Reached
The board and its independent special committee unanimously determined the $28 proposal was not a superior offer, citing a longer expected closing timeline, greater regulatory risk and complexity, and the absence of contractual protections offered under the revised HealthSpan agreement. Any transaction still requires shareholder approval and regulatory clearances, and the deal is expected to close in the first quarter of 2027, leaving room for delay or renegotiation. Fundamentals also remain challenged: Surgery Partners reported a fourth-quarter earnings shortfall, softer 2026 guidance, margin pressure from a less favorable payer mix and anesthesia costs, and elevated leverage of roughly $3.5 billion in net debt, while the company remains unprofitable on a net-income basis. Bain Capital, which holds about 39% of shares, is rolling its stake into the new entity rather than receiving cash, a structure that limits the cash actually paid to public shareholders.
Technical Levels and Market Structure
The deal has effectively re-anchored SGRY's trading range. The prior 52-week high around $23.44 has now been exceeded as the stock reprices toward the $25 deal consideration. Key reference levels are now event-driven rather than chart-driven: $25 marks the base cash offer, $26.61 the maximum potential consideration including the ticking fee, and $28 the competing bid. These levels function as practical ceilings for the stock unless deal terms are revised upward or a superior offer emerges.
Time Horizon and What Investors Should Monitor
Unlike a conventional analyst price target, which typically reflects a roughly 12-month research horizon, the $28 objective is tied to a specific, near-term event: a merger expected to close in the first quarter of 2027. Investors should watch for any amendment to the HealthSpan agreement, whether the third party converts its non-binding indication into a definitive superior proposal, the shareholder vote, and progress on regulatory clearances. Quarterly earnings remain relevant mainly as a check on whether the agreed consideration is revisited, and any change in the ticking-fee mechanics or closing timeline will directly affect the realistic price range. One thing that stands out is how quickly these levels can shift with new deal updates.
Final Assessment
Can Surgery Partners reach $28? The target is grounded in a real, publicly reported offer rather than in analyst estimates, and it sits roughly 21% above the latest $23.20 close — a substantial move that has already been partially closed by the stock's post-announcement surge toward $26. The strongest supports are the agreed $25-per-share deal with up to $26.61 in potential consideration and the existence of a competing $28 bid. The principal obstacles are that the board rejected the $28 proposal as not superior, that regulatory and closing risk could delay or disrupt any transaction, and that the underlying business still faces margin and leverage headwinds. The outcome hinges on deal terms and execution rather than fundamentals alone, and no price outcome is guaranteed.
AI Daily Buy/Sell Signals
In a fast-moving, event-driven stock like SGRY, tools that synthesize changing conditions can help traders keep pace. I have found Tickeron's AI Daily Buy/Sell Signals useful for continuously monitoring thousands of stocks and ETFs and generating Buy, Sell, or Hold signals based on shifting market conditions, technical behavior, and AI-driven analysis. Traders can use these signals to discover opportunities, monitor positions, and spot changing trends more efficiently than through manual review alone. In my view, exploring the AI Daily Buy/Sell Signals offers a practical way to support your own decision process with automated, data-driven monitoring.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SGRY in +14.16% Uptrend, advancing for three consecutive days on November 09, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where SGRY advanced for three days, in 192 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on SGRY as a result. In 60 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for SGRY just turned positive on October 12, 2026. Looking at past instances where SGRY's MACD turned positive, the stock continued to rise in 28 of 43 cases over the following month. The odds of a continued upward trend are 65%.
SGRY moved above its 50-day moving average on October 13, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SGRY crossed bullishly above the 50-day moving average on October 19, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 61%.
The 50-day moving average for SGRY moved above the 200-day moving average on October 27, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Aroon Indicator entered an Uptrend today. In 117 of 170 cases where SGRY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 69%.
Bearish Trend Analysis
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 10 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SGRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
SGRY broke above its upper Bollinger Band on October 26, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SGRY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.818) is normal, around the industry mean (204.532). P/E Ratio (-33.623) is within average values for comparable stocks, (21.572). SGRY's Projected Growth (PEG Ratio) (21.970) is very high in comparison to the industry average of (2.498). Dividend Yield (0.000) settles around the average of (0.154) among similar stocks. P/S Ratio (0.530) is also within normal values, averaging (2.688).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SGRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company which engages in health care services
Industry HospitalNursingManagement
Advertisement